STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.

Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.

Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.

Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.

Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of

Rhea-AI Summary

Amgen will report its first quarter 2024 financial results on May 2, 2024, followed by a conference call with the investment community. The webcast will be available on their website for replay for at least 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
-
Rhea-AI Summary

Amgen (AMGN) is set to submit a Marketing Authorization Application to the European Medicines Agency for teprotumumab, a treatment for Thyroid Eye Disease. If approved, it would be the first medicine for this condition in the EU. Clinical studies have shown significant improvements in symptoms, with early proptosis improvement seen at six weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
Rhea-AI Summary
Amgen announces positive results from the Phase 2a COURSE trial for TEZSPIRE® in COPD, showing a reduction in annualized rate of moderate or severe exacerbations by 17%. Planning for Phase 3 development of tezepelumab is underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
conferences clinical trial
Rhea-AI Summary
Amgen announces positive 52-week data for Otezla in children with plaque psoriasis and successful late-breaking Phase 3 study results for palmoplantar pustulosis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Amgen (AMGN) declares $2.25 per share dividend for Q2 2024, payable on June 7, 2024, to stockholders of record as of May 17, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
dividends
-
Rhea-AI Summary
Amgen (NASDAQ:AMGN) executives to present at the 44th Annual TD Cowen Health Care Conference. Webcast available for investors and the public. Amgen launches 'Amgen Perspectives in Obesity' website for additional information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
conferences
Rhea-AI Summary
Amgen (AMGN) unveils its cutting-edge manufacturing facility, Amgen Ohio, in Central Ohio. The facility, spanning 300,000 square feet, will employ 400 staff, focusing on innovative biomedicines. Amgen aims for carbon neutrality by 2027, emphasizing sustainability. The site also supports the local community through job creation and a manufacturing apprenticeship program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
-
Rhea-AI Summary
Amgen (AMGN) will host a webcast to discuss Rare Disease as its new growth pillar, highlighting strategies, products, and pipeline opportunities. Key executives will participate in the conference call, emphasizing the company's focus on rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
conferences
-
Rhea-AI Summary
Amgen (AMGN) executives to present at Oppenheimer Healthcare Life Sciences Conference. Webcast available for replay on Amgen's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
conferences
Rhea-AI Summary
Amgen (AMGN) reported a 20% increase in total revenues for the fourth quarter of 2023, driven by a 23% volume growth in product sales. However, GAAP earnings per share decreased by 53% due to acquisition-related expenses and incremental operating expenses from Horizon. Non-GAAP EPS increased by 15% for the quarter. The company generated $7.4 billion of free cash flow for the full year, primarily driven by transaction expenses related to the Horizon acquisition and higher repatriation tax payments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.39%
Tags

FAQ

What is the current stock price of Amgen (AMGN)?

The current stock price of Amgen (AMGN) is $264 as of December 23, 2024.

What is the market cap of Amgen (AMGN)?

The market cap of Amgen (AMGN) is approximately 140.8B.

Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

140.76B
536.09M
0.21%
81.11%
1.82%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS